All articles tagged with #vertex pharmaceuticals
Three scientists, including researchers from Vertex Pharmaceuticals and the University of Iowa, received the prestigious Lasker Award for their groundbreaking work that significantly improved cystic fibrosis treatment and extended patient lifespans.
Three scientists from Vertex Pharmaceuticals and the University of Iowa received the prestigious Lasker Award for their groundbreaking work that significantly improved treatment and extended the lives of cystic fibrosis patients.
Vertex Pharmaceuticals announced that its experimental pain drug VX-993 failed to outperform placebo in a Phase 2 trial, leading to the discontinuation of its development as a single-agent for acute pain, though the company will continue testing it for chronic nerve pain in diabetic patients.
A small stem cell trial using zimislecel by Vertex Pharmaceuticals has temporarily cured or significantly reduced insulin dependence in 10 out of 12 severe Type 1 diabetes patients, offering hope for future treatments.
A study presented at the American Diabetes Association's meeting shows that an off-the-shelf stem cell therapy called zimislecel enabled 10 out of 12 participants with type 1 diabetes to produce their own insulin and maintain healthy blood glucose levels for at least a year, with no severe hypoglycemia episodes reported after three months.
Vertex Pharmaceuticals has filed a lawsuit against the U.S. government to allow the company to fund fertility preservation services for patients receiving Casgevy, a CRISPR-based treatment for sickle cell disease. The lawsuit challenges an oral opinion from the Health and Human Services Office of the Inspector General, which deemed the program a violation of federal anti-kickback laws. Vertex argues that the program is essential for patients who must undergo chemotherapy, which can cause infertility, and that the refusal to allow such support exacerbates healthcare inequalities.
Vertex Pharmaceuticals announced its acquisition of Alpine Immune Sciences for $4.9 billion, causing Alpine's stock to surge by 37%. The deal is expected to close later this quarter and values Alpine stock at $65 per share, representing a 67% premium to Tuesday's close. Analysts believe Alpine's potential best-in-class treatment for IgA nephropathy, povetacicept, has the potential to lead its class due to its superior APRIL/BAFF inhibition and convenient dosing regimen. The acquisition reflects Vertex's confidence in Alpine's drug and its potential in treating autoimmune conditions. Vertex's stock also rose 1% following the announcement.
Stock futures dipped as traders anticipated another inflation report, with Dow Jones Industrial Average, S&P 500, and Nasdaq-100 futures all sliding. The market reacted to a hot March inflation reading, prompting concerns about potential Federal Reserve rate cuts. The next key inflation tests come with March's producer price index and weekly jobless claims. Additionally, Vertex Pharmaceuticals announced its acquisition of Alpine Immune Sciences, causing shares to fluctuate.
Vertex Pharmaceuticals Inc. is set to acquire Alpine Immune Sciences Inc. for approximately $4.9 billion, marking its largest acquisition to date. The deal will see Vertex pay $65 per share in cash for Alpine, a 67% premium over its closing price on Tuesday. The acquisition comes as Vertex looks to expand its portfolio with Alpine's immune treatments, while Alpine's stock surged 21% following reports of the potential sale.
Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion in cash, gaining access to the biotech firm's treatment for IgA nephropathy, an autoimmune disease of the kidney. The deal will provide Vertex with access to Alpine's povetacicept, a mid-stage treatment for IgAN, which targets proteins contributing to autoimmune and antibody diseases. The acquisition aligns with Vertex's focus on expanding its portfolio beyond cystic fibrosis and blood disorders, and the deal is expected to close in the second quarter of 2024.
South African patients with cystic fibrosis are taking legal action against Vertex Pharmaceuticals for access to the life-changing drug Trikafta, which costs $326,000 a year per patient. The lawsuit accuses the company of patent abuse and violating patients' human rights, as the drug is unaffordable for most. While Vertex defends its intellectual property rights, patients are resorting to importing a generic version from Argentina at a fraction of the cost. The legal battle highlights the challenges of accessing expensive medication in low- and middle-income countries, leaving many patients without life-saving treatment.
Latigo Biotherapeutics, a non-opioid drug developer, has emerged with a $135 million Series A funding after years of development, targeting the same Nav1.8 as Vertex Pharmaceuticals. The company aims to address pain management without the risk of addiction by focusing on the peripheral nervous system.
Vertex Pharmaceuticals' experimental non-opioid painkiller, VX-548, successfully reduced acute, post-surgical pain without the risk of addiction in late-stage trials, although it did not outperform a combination of opioid drugs. The drug, which aims to block pain signals at their source, is expected to be submitted for U.S. approval by mid-2024 and could potentially generate over $5 billion in annual sales. Analysts view this as a significant advancement in providing a much-needed alternative to addictive opioid painkillers amidst a national crisis.
Vertex Pharmaceuticals' non-opioid painkiller, VX-548, has shown promising results in two large clinical trials for treating acute pain after surgery, offering hope for an alternative to opioid medications. While the drug demonstrated significant pain relief and faster onset compared to a placebo, it did not outperform a combination of hydrocodone bitartrate and Tylenol. Despite this, the drug's safety profile and effectiveness in reducing pain intensity are encouraging, with plans to seek FDA approval by mid-year. If successful, VX-548 could address the urgent need for potent, safe, and non-addictive analgesics, potentially marking the beginning of a new class of pain drugs.
Vertex Pharmaceuticals has developed an experimental drug, VX-548, that targets moderate to severe acute pain by blocking pain signals at the source, potentially avoiding the risk of addiction associated with opioids. The company reported positive results from two randomized studies and plans to seek FDA approval for the drug by midyear. If approved, this non-opioid medication could offer a new approach to pain relief, with potential implications for addressing the opioid addiction crisis.